Therefore, the use of surgically resected CRC for immunotherapy to specifically activate the protective CD8<sup>+</sup> T cells against their own cancer cells is a valuable approach to prevent the recurrence of cancer. The gene discussed is CD8A; the disease is colorectal carcinoma.